Welcome to our dedicated page for Nuwellis news (Ticker: $NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuwellis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuwellis's position in the market.
Nuwellis, Inc. (Nasdaq: NUWE) has received a Notice of Allowance from the USPTO for a patent related to its innovative pediatric Continuous Renal Replacement Therapy (CRRT) device Vivian™. This patent enhances Nuwellis' IP portfolio, enabling healthcare providers to seamlessly switch between stationary and transport modes for improved patient care. The company is also developing a new pediatric CRRT device with NIH funding, in collaboration with Koronis Biomedical Technologies , to better care for children with kidney issues.
Nuwellis, Inc. announced the closing of a $2.7 million public offering, issuing 11,250,000 shares of common stock and warrants. The gross proceeds will be used for working capital and general corporate purposes, including investments in commercialization efforts.
Nuwellis, Inc. (NUWE) will report its first quarter 2024 financial results on May 7, 2024. The medical technology company will host a conference call and webcast to discuss the results and provide a business update.
Nuwellis, Inc. (NUWE) announced the pricing of a $2.7 million public offering, including 11,250,000 shares of common stock and warrants to purchase up to 16,875,000 shares at $0.24 per share. Each share comes with a warrant to purchase 1.5 additional shares at an exercise price of $0.40 per share.
